Cellumed
셀루메드 · 049180
Health Care Pharmaceuticals · KOSDAQ
Market cap US$60.9M (₩84B)
Overview
Cellumed makes products used in bone and joint repair, including bone graft materials, total knee replacement implants, and a joint-fluid substitute that eases knee pain.
Its customers are primarily hospitals and surgical teams that use these materials in orthopaedic procedures. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across three areas, medical devices, biologics (protein-based therapeutics), and cosmeceuticals, while also pursuing enzyme production for messenger-RNA vaccines through a contract-development arrangement with a German partner.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$69.2M
- FY2024US$93.6M
- FY2025US$101.6M
Operating profit
- FY2023−US$7.6M
- FY2024−US$5M
- FY2025−US$3.7M
Net income
- FY2023−US$27.5M
- FY2024−US$23.1M
- FY2025−US$1.6M
Key ratios (FY2025)
Why it matters
Cellumed consolidates several subsidiaries under its group, including a biologics unit and environmental and real-estate construction companies, making it a diversified holding structure rather than a pure medical-device business.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?